Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the ...

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging ...

In this video from the National Kidney Foundation Spring Clinical Meetings, Jared R. Hassler, MD, shares highlights from his ...

IgA nephropathy (IgAN) is a kidney disorder caused by a buildup of immune complexes and the antibody called immunoglobulin A (IgA) inside the kidneys. This buildup causes inflammation in the kidneys.

Second agent targeting BAFF and APRIL appears effective in phase III trial ...

The trial will enrol 30 participants diagnosed with IgAN.

Diabetic nephropathy is a common complication associated with diabetes that affects a person’s kidneys. Several medications may help slow the progression of kidney damage. Early treatment can prevent ...

Though not everyone with IgA nephropathy deals with end-stage kidney disease, around 25% of them face this complication. But there may be another option: a clinical trial. Depending on what’s ...

A new pathologic classification scheme for diabetic nephropathy, in which only glomerular lesions are used to classify renal damage associated with either type 1 or type 2 diabetes, has been developed ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...